Advances in sarcoma genomics and new therapeutic targets
Nature Reviews Cancer, ISSN: 1474-175X, Vol: 11, Issue: 8, Page: 541-557
2011
- 332Citations
- 427Captures
Metric Options: CountsSelecting the 1-year or 3-year option will change the metrics count to percentiles, illustrating how an article or review compares to other articles or reviews within the selected time period in the same journal. Selecting the 1-year option compares the metrics against other articles/reviews that were also published in the same calendar year. Selecting the 3-year option compares the metrics against other articles/reviews that were also published in the same calendar year plus the two years prior.
Example: if you select the 1-year option for an article published in 2019 and a metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019. If you select the 3-year option for the same article published in 2019 and the metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019, 2018 and 2017.
Citation Benchmarking is provided by Scopus and SciVal and is different from the metrics context provided by PlumX Metrics.
Example: if you select the 1-year option for an article published in 2019 and a metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019. If you select the 3-year option for the same article published in 2019 and the metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019, 2018 and 2017.
Citation Benchmarking is provided by Scopus and SciVal and is different from the metrics context provided by PlumX Metrics.
Metrics Details
- Citations332
- Citation Indexes332
- 332
- CrossRef306
- Captures427
- Readers427
- 427
Review Description
Increasingly, human mesenchymal malignancies are being classified by the abnormalities that drive their pathogenesis. Although many of these aberrations are highly prevalent within particular sarcoma subtypes, few are currently targeted therapeutically. Indeed, most subtypes of sarcoma are still treated with traditional therapeutic modalities, and in many cases sarcomas are resistant to adjuvant therapies. In this Review, we discuss the core molecular determinants of sarcomagenesis and emphasize the emerging genomic and functional genetic approaches that, coupled with novel therapeutic strategies, have the potential to transform the care of patients with sarcoma. © 2011 Macmillan Publishers Limited. All rights reserved.
Bibliographic Details
http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&scp=79960847016&origin=inward; http://dx.doi.org/10.1038/nrc3087; http://www.ncbi.nlm.nih.gov/pubmed/21753790; https://facultyopinions.com/prime/12389956#eval13587054; http://dx.doi.org/10.3410/f.12389956.13587054; https://www.nature.com/articles/nrc3087; https://dx.doi.org/10.1038/nrc3087; http://f1000.com/12389956#eval13587054; https://f1000.com/prime/12389956#eval13587054
Faculty Opinions Ltd
Provide Feedback
Have ideas for a new metric? Would you like to see something else here?Let us know